A landmark week across oncology, with pivotal data in lung, prostate, bladder, and haematological cancers reshaping treatment paradigms in both early and advanced disease. Gene editing, RNA therapeutics, and AI drug discovery attracted major capital commitments. Kidney disease emerged as a strategic battleground. A persistent US drug pricing gap versus other high-income countries remained unresolved.

AI integration moves from experimentation to enterprise-wide deployment. Clinical readouts reinforce the difficulty of beating established immunotherapy standards, while positive data in infection, rare disease & metabolic disease highlight ongoing unmet need. A meaningful regulatory approval addresses treatment-resistant hypertension. Biosimilar launches continue to erode branded franchises. Across the week, the gap between scientific promise and commercial reality remains a